Table 1.
Pediatric clinical trials with FLT3 inhibitors: recently completed or ongoing studies.
| Trial identifier | Phase | Status | Patients | Drug(s) | Results |
|---|---|---|---|---|---|
| NCT00469859 COG AAML06P1 | 1/2 | Completed | Relapsed AML | Lestaurtinib (CEP-701) Cytarabine Idarubicin | Not published |
| NCT00557193 COG-AALL0631 | 3 | Completed | Newly diagnosed ALL Infants <12 m | Lestaurtinib (CEP-701) Chemotherapy (modified P9407) | Not published |
| NCT00866281 | 1/2 | Recruiting | MLL-r infant ALL FLT3-mutant AML | Midostaurin (PKC412) | N/A |
| NCT01411267 TACL 2009-004 | 1 | Completed | Relapsed/refractory ALL or AML | Quizartinib (AC220) Cytarabine Etoposide Methotrexate | Not published; Abstract presented at ASH 2013 |
| NCT00908167 St. Jude RELHEM | 1 | Recruiting | Relapsed/refractory ALL or AML | Sorafenib Cytarabine Clofarabine | N/A; although pilot cohort data published: Inaba et al. (111) |
| NCT00665990 St. Jude ANGIO1 | 1 | Recruiting | Refractory ALL, AML or solid tumors (solid tumor portion completed) | Sorafenib Bevacizumab Low dose-cytoxan | N/A |
| NCT01371981 COG AAML1031 | 3 | Recruiting | Newly diagnosed AML | Sorafenib Bortezomib Chemotherapy (ADE or ADE/MA based) | N/A |
| NCT01445080 | 1 | Completed | Refractory ALL, AML or solid tumors | Sorafenib | Published; Widemann et al. (112) |
Trial information from www.clinicaltrials.gov referenced July, 2014.